We're looking for scientists across our network to work with some of the world's leading Cell & Gene Therapy (CGT) experts. Browse our available CGT positions here.
The French drugmaker, having hit delays with its own coronavirus shot, agreed to manufacture over 125 million doses of Pfizer and BioNTech's vaccine for supply in Europe.
The drugmaker, one of the largest vaccine developers, won't move forward with two candidates it's been testing after disappointing data in early trials.
The experimental treatment from Asahi Kasei Pharma adds to Lilly's pipeline of drugs for pain, including a non-opioid medicine now under review at the FDA.
Lupkynis, the first oral drug approved for lupus nephritis, comes with a high list price. Its developer, Aurinia Pharmaceuticals, expects average net revenue of roughly $65,000 per patient per year.
Results from the large Phase 3 trial are highly anticipated. If proven effective, J&J's shot could provide much-needed reinforcements to a constrained immunization effort.
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.
BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries.
This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255 23rd Street NW, Suite 550, Washington, DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.
No comments:
Post a Comment